Previous 10 | Next 10 |
Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023 PR Newswire BOSTON and ATLANTA , May 8, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company dev...
Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference PR Newswire BOSTON and ATLANTA , May 4, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company de...
Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease PR Newswire - State-of-the-art biomarker analyses a hallmark of the 201 study - BOSTON and ATLANTA , April 26...
Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase PR Newswire BOSTON and ATLANTA , April 21, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing...
2023-04-03 13:29:06 ET Inhibikase Therapeutics, Inc. (IKT) Q4 2022 Earnings Conference Call April 3, 2023 08:00 ET Company Participants Alex Lobo - Stern Investor Relations Milton Werner - President & Chief Executive Officer Joe Frattaroli - Chief Financial O...
2023-03-31 08:52:50 ET Inhibikase Therapeutics press release ( NASDAQ: IKT ): FY GAAP EPS of -$0.72. Revenue of $0.1M (-96.8% Y/Y). Cash, cash equivalents and marketable securities were $23.1 million as of December 31, 2022. Selling, general and administrative expe...
Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity PR Newswire BOSTON and ATLANTA , March 31, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharma...
Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023 PR Newswire BOSTON and ATLANTA , March 23, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-st...
Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders PR Newswire BOSTON and ATLANTA , March 21, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("In...
2023-03-16 09:33:00 ET When searching for penny stocks to buy or penny stocks to watch, it’s good to focus on catalysts. Typically valued under $5 per share, these stocks generally attract small and new investors. Even with the glitz and glamour that comes with massive breakouts,...
News, Short Squeeze, Breakout and More Instantly...
Inhibikase Therapeutics Inc. Company Name:
IKT Stock Symbol:
NASDAQ Market:
Inhibikase Therapeutics Inc. Website:
BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...
- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kin...
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson...